CEPHEID
 (CPHD)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Oct. 14, 2015, 12:46 PM
    | Oct. 14, 2015, 12:46 PM
  • Oct. 14, 2015, 9:13 AM
    | Oct. 14, 2015, 9:13 AM | 11 Comments
  • Oct. 13, 2015, 5:38 PM
    | Oct. 13, 2015, 5:38 PM | 3 Comments
  • Jul. 18, 2014, 12:45 PM
    | Jul. 18, 2014, 12:45 PM
  • Jul. 17, 2014, 5:35 PM
    | Jul. 17, 2014, 5:35 PM | 1 Comment
  • Jan. 31, 2014, 12:46 PM
    | Jan. 31, 2014, 12:46 PM
  • Jan. 30, 2014, 5:36 PM
    • Top gainers, as of 5:15 p.m.: ZNGA +23.0%. UIS +12.4%. PFPT +12.2%. CPHD +10.0%. MTW +9.1%.
    • Top losers, as of 5:15 p.m.: DLLR -20.5%. HGR -13.0%. GDOT -11.1%. ABAX -10.6%. TNP -10.0%.
    | Jan. 30, 2014, 5:36 PM | 7 Comments
  • Jan. 30, 2014, 4:14 PM
    • CEPHEID (CPHD): Q4 EPS of $0.03 beats by $0.02.
    • Revenue of $113.3M (+22.6% Y/Y) beats by $11.13M.
    • Shares +10.1%.
    | Jan. 30, 2014, 4:14 PM
  • Oct. 17, 2013, 5:42 PM
    | Oct. 17, 2013, 5:42 PM | 6 Comments
  • Oct. 17, 2013, 4:23 PM
    • Cepheid (CPHD): Q3 EPS of $0.09 beats by $0.10.
    • Revenue of $100.1M (+24% Y/Y) beats by $6.4M. Shares +3.9% AH. (PR)
    | Oct. 17, 2013, 4:23 PM
  • Oct. 4, 2013, 12:09 PM
    • Cepheid (CPHD -2.7%)┬áslips as ISI's Vijay Kumar downgrades the shares to Sell from Cautious.
    • Kumar cites increased competition, slowing base business, limited upside, pricing pressure, and "structurally higher cost of goods sold."
    • ISI sees revenue below consensus, which it says should "continue to drift lower over the next few quarters."
    • Q3 earnings are due on the 17th.
    | Oct. 4, 2013, 12:09 PM
  • Jul. 19, 2013, 5:32 PM
    After-hours top gainers, as of 5:15 p.m.: DRIV +3%. CYT +2%. SRC +2%. STAG +1%. PBI +1%.
    After-hours top losers: EPOL -4%. CPHD -4%. TSYS -3%. FLOW -3%. CYH -3%.
    | Jul. 19, 2013, 5:32 PM | 1 Comment
  • Jul. 11, 2013, 4:21 PM

    Cepheid (CPHD) reports preliminary Q2 results: GAAP net loss of $0.10/ share and non-GAAP net income of $0.02/ share on revenue of ~$96M. CEO John Bishop says "record revenue and associated production volume" show the company made "good progress" on allaying investor concerns regarding Xpert test availability. Shares +2.7% AH. (PR)

    | Jul. 11, 2013, 4:21 PM
  • Jun. 26, 2013, 10:53 AM

    Cepheid (CPHD +3.4%) moves up today after coverage is resumed at Oppenheimer with an Outperform and a $41 price target.

    | Jun. 26, 2013, 10:53 AM
  • May 31, 2013, 3:52 PM

    Cepheid (CPHD -4.4%) slides after Jefferies analyst Brandon Couillard assumes coverage of the shares with a downgrade to Hold, but reiterates the $38 price target. Couillard says that the company is well-positioned for margin expansion over the longer term as it leverages investments in its R&D pipeline, launches new high-margined tests and captures greater manufacturing efficiencies, but present valuations are already reflecting these bullish growth expectations.

    | May 31, 2013, 3:52 PM
  • Apr. 18, 2013, 5:53 PM
    After-hours top gainers, as of 5:15 p.m.: RH +8%. IMRS +6%. BGS +5%. CPHD +5%. PRLB +5%.
    After-hours top losers: AIRM -15%. CIE -6%. LSCC -5%. AMD -5%. TAHO -4%.
    | Apr. 18, 2013, 5:53 PM
Company Description
Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical market.